Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxidectin + triclabendazole
- Development stage
- Unknown
- Lead developer
- Wayzon Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Cydectin + Triclamox is a veterinary anthelmintic combination product marketed by Wayzon Pharma, containing the active ingredients moxidectin and triclabendazole. Moxidectin is a second-generation macrocyclic lactone of the milbemycin class that provides potent, broad-spectrum activity against gastrointestinal roundworms, lungworms, and certain ectoparasites by binding to glutamate-gated chloride channels, leading to hyperpolarization and flaccid paralysis of the parasite. Triclabendazole is a benzimidazole derivative uniquely effective against all stages of the liver fluke (Fasciola hepatica), from early immature to adult forms, by interfering with tubulin polymerization and microtubule-dependent processes. This combination is primarily indicated for the treatment and control of mixed infections of moxidectin-sensitive nematodes and triclabendazole-sensitive liver flukes in livestock such as sheep and cattle.
- Brand names
- Cydectin TriclamoxCydectin + Triclamox
- Other names
- moxidectin and triclabendazole
02
Targets
GluCl (Glutamate-gated chloride channel)TUBB (Tubulin (alpha and beta subunits))RDL (Insect GABA-gated chloride channel)
Beyond the preview
Go deeper on moxidectin + triclabendazole.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moxidectin + triclabendazole.